Silexion Therapeutics Corp. (NASDAQ: SLXN), a clinical-stage biotechnology company, has announced its participation in the 2024 Maxim Healthcare Virtual Summit, scheduled from October 15 to 17, 2024. The company will feature in a fireside chat on Thursday, October 17, 2024, at 9:30am ET, offering insights into its development of RNA interference (RNAi) therapies for KRAS-driven cancers. The discussion will be hosted by Jason McCarthy, Senior Managing Director and Head of Biotechnology Research at Maxim Group, and will include Silexion's leadership team, CEO Ilan Hadar and Chief Scientific and Development Officer Dr. Mitchell Shirvan.
This presentation provides a significant platform for Silexion to communicate its progress and strategy to investors and healthcare professionals. The company focuses on addressing KRAS-driven cancers, which are the most common oncogenic driver in human cancers, representing a critical unmet need, particularly for patients with difficult-to-treat solid tumors. Silexion's innovative approach using RNAi technology aims to target these cancers effectively.
The company's lead product, LODER™, has demonstrated promising results in a Phase 2 trial for non-resectable pancreatic cancer, a notoriously challenging disease. Additionally, Silexion is advancing its next-generation siRNA candidate, SIL-204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. Participation in events like the Maxim Healthcare Virtual Summit is crucial for building awareness and support for such innovative therapies.
The fireside chat will be streamed live on M-Vest, Maxim Group's digital conference platform, accessible to registered members, allowing for real-time engagement and transparency regarding the company's progress. In addition to the presentation, Silexion's management team will be available for one-on-one meetings throughout the summit, offering opportunities for deeper engagement with investors and potential partners in the biotech sector.
For investors and industry observers, this event offers a chance to assess Silexion's position in the competitive landscape of cancer therapeutics. The company's focus on KRAS-driven cancers, implicated in a significant proportion of human cancers, underscores the potential broad applicability and market impact of their therapies if successfully developed. As the biotechnology industry evolves rapidly, summits like this play a key role in connecting innovative companies with stakeholders, influencing investment decisions and research directions.
Silexion Therapeutics' participation highlights the growing interest in RNAi-based therapies and their potential to transform cancer treatment. As the company advances its clinical programs and expands its pipeline, such high-profile presentations are critical for fostering collaborations and advancing the fight against challenging cancers. The virtual format of the summit enhances accessibility, enabling a wider audience to gain insights into these promising therapeutic approaches.
